GlassScriptPhysician profile
Alison M Dolce
NPI 1962662726
$31,080.60
in general payments reported to CMS, 2019-2025
16 companies · $4,128 in 2025
The $4,128 reported for 2025 was more than what 84% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.46 · 2022: $151 · 2023: $2,223 · 2024: $25K · 2025: $4,128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Consulting Fee: $7,344 · Travel and Lodging: $3,450 · Food and Beverage: $2,284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,812.00 |
| Consulting Fee | $7,344.00 |
| Travel and Lodging | $3,449.88 |
| Food and Beverage | $2,284.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Immedica Pharma US, INC. | $20,701.87 | 2023-2024 | |
| Otter Pharmaceuticals, LLC | $5,788.65 | 2024-2025 | Sympazan |
| Ucb, INC. | $3,635.52 | 2024-2025 | Fintepla, Briviact |
| Sk Life Science, INC. | $170.31 | 2025 | |
| Livanova USA, INC. | $159.44 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Allergan, INC. | $151.10 | 2022 | |
| Biocodex, INC. | $145.40 | 2025 | |
| Jazz Pharmaceuticals INC. | $135.98 | 2025 | |
| Upsher-Smith Laboratories LLC | $70.63 | 2025 | |
| Acadia Pharmaceuticals INC | $26.76 | 2025 | Daybue |
| Aquestive Therapeutics, INC. | $22.03 | 2019 | |
| Neurelis, INC. | $21.98 | 2025 | Valtoco |
| Greenwich Biosciences, INC. | $17.43 | 2019 | |
| Aucta Pharmaceuticals, INC. | $17.38 | 2025 | Motpoly Xr |
| Neuropace, INC. | $16.12 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alison Dolce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.